Literature DB >> 12211426

Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone.

Daniel D Bikle1, Takeshi Sakata, Colin Leary, Hashem Elalieh, David Ginzinger, Clifford J Rosen, Wesley Beamer, Sharmila Majumdar, Bernard P Halloran.   

Abstract

Parathyroid hormone (PTH) is a potent anabolic agent for bone, but the mechanism(s) by which it works remains imperfectly understood. Previous studies have indicated that PTH stimulates insulin-like growth factor (IGF) I production, but it remains uncertain whether IGF-I mediates some or all of the skeletal actions of PTH. To address this question, we examined the skeletal response to PTH in IGF-I-deficient (knockout [k/o]) mice. These mice and their normal littermates (NLMs) were given daily injections of PTH (80 microg/kg) or vehicle for 2 weeks after which their tibias were examined for fat-free weight (FFW), bone mineral content, bone structure, and bone formation rate (BFR), and their femurs were assessed for mRNA levels of osteoblast differentiation markers. In wild-type mice, PTH increased FFW, periosteal BFR, and cortical thickness (C.Th) of the proximal tibia while reducing trabecular bone volume (BV); these responses were not seen in the k/o mice. The k/o mice had normal mRNA levels of the PTH receptor and increased mRNA levels of the IGF-I receptor but markedly reduced basal mRNA levels of the osteoblast markers. Surprisingly, these mRNAs in the k/o bones increased several-fold more in response to PTH than the mRNAs in the bones from their wild-type littermates. These results indicate that IGF-I is required for the anabolic actions of PTH on bone formation, but the defect lies distal to the initial response of the osteoblast to PTH.

Entities:  

Keywords:  NASA Discipline Musculoskeletal; Non-NASA Center

Mesh:

Substances:

Year:  2002        PMID: 12211426     DOI: 10.1359/jbmr.2002.17.9.1570

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  87 in total

1.  Proteoglycan 4: a dynamic regulator of skeletogenesis and parathyroid hormone skeletal anabolism.

Authors:  Chad M Novince; Megan N Michalski; Amy J Koh; Benjamin P Sinder; Payam Entezami; Matthew R Eber; Glenda J Pettway; Thomas J Rosol; Thomas J Wronski; Ken M Kozloff; Laurie K McCauley
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

2.  Effects of age on parathyroid hormone signaling in human marrow stromal cells.

Authors:  Shuanhu Zhou; Ericka M Bueno; Sung Won Kim; Ilaria Amato; Longxiang Shen; Jochen Hahne; Ilan Bleiberg; Paul Morley; Julie Glowacki
Journal:  Aging Cell       Date:  2011-05-25       Impact factor: 9.304

Review 3.  Osteoblastogenesis regulation signals in bone remodeling.

Authors:  C Zuo; Y Huang; R Bajis; M Sahih; Y-P Li; K Dai; X Zhang
Journal:  Osteoporos Int       Date:  2012-06       Impact factor: 4.507

Review 4.  Autocrine and Paracrine Actions of IGF-I Signaling in Skeletal Development.

Authors:  Yongmei Wang; Daniel D Bikle; Wenhan Chang
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

Review 5.  Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis.

Authors:  T J Martin; N A Sims; K W Ng
Journal:  Osteoporos Int       Date:  2008-03-13       Impact factor: 4.507

6.  Analysis of OPLA scaffolds for bone engineering constructs using human jaw periosteal cells.

Authors:  Dorothea Alexander; Jürgen Hoffmann; Adelheid Munz; Björn Friedrich; Jürgen Geis-Gerstorfer; Siegmar Reinert
Journal:  J Mater Sci Mater Med       Date:  2007-12-25       Impact factor: 3.896

7.  Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.

Authors:  Manshan Xu; Shilpa Choudhary; Olga Voznesensky; Qi Gao; Douglas Adams; Vilmaris Diaz-Doran; Qian Wu; David Goltzman; Lawrence G Raisz; Carol C Pilbeam
Journal:  Bone       Date:  2010-05-13       Impact factor: 4.398

8.  Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment.

Authors:  P J Niziolek; S Murthy; S N Ellis; K B Sukhija; T A Hornberger; C H Turner; A G Robling
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

Review 9.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

10.  Nmp4/CIZ suppresses parathyroid hormone-induced increases in trabecular bone.

Authors:  Alexander G Robling; Paul Childress; Jun Yu; Jessica Cotte; Aaron Heller; Binu K Philip; Joseph P Bidwell
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.